Celbopag 25mg Tablet

Celbopag 25mg tablet is a prescription based medication is used in the treatment of hepatitis C and manage low platelet count. It helps manage the infection and supports liver health as part of a prescribed therapy. Its active ingredient is Eltrombopag Olamine and belongs to the drug class of thrombopoietin receptor agonists (TPO-RAs). The medicine works by stimulating the production of platelets in the bone marrow, helping to increase low platelets in patients with hepatitis C. Doctor provide this medication under strict guidelines to ensure safety and effectiveness of the medication.

Treat hepatitis C and manage low platelet count

Celbopag 25mg tablet caused acute and severe side effects but it can be managed with proper treatment. Here are some common side effects, consult the doctor if any of these symptoms persist:
● Common cold
● Cough
● Respiratory tract infection
● Back pain
● High temperature, cough
● Loss of appetite
● Hair loss
● Swelling in feet or hands
● Headache, dizziness
● Mouth and throat pain
● Joint pain
● Diarrhea, abdominal pain
● Common cold

Celbopag 25mg tablet should be taken on an empty stomach. Doctor's prescription is much needed while using the medicine. The medicine should be swallowed whole, do not chew or crush the tablet as it may reduce the effectiveness of the medication. The correct dosage and duration is administered by a healthcare professional. Follow the doctor's guidance as recommended for safety purposes.

Celbopag 25mg tablet contains Thrombopoietin receptor agonists belongs to the drug class. It helps to increase the platelets and works as natural hormone thromobopoietin. It stimulates the bone marrow to produce more platelets. It is commonly prescribed for conditions where platelet counts are low, such as chronic immune thromobocytopenia (ITP). It helps reduce the risk of bleeding and improve overall platelet in patients with requiring long-term management.

• Dandabattina, R., Subramanian, V. B., Merugu, K. S., SharathBabu, H., Katari, N. K., & Kowtharapu, L. P. (2023). Stability-indicating RP-HPLC method development and validation for eltrombopag olamine in the presence of impurities and degradation products. Robustness by design of expert software. Journal of AOAC International, 106(2), 267-275.
• Ganorkar, S. B., Bobade, P. S., Prabhu, R. C., Lokwani, D. K., Shinde, R. N., Telange, D. R., ... & Vander Heyden, Y. (2024). Extension of impurity profiling on eltrombopag olamine to in-silico predictions: An effort to exploit correlated forced degradation products and known drug-related substances in drug discovery. Journal of Chromatography B, 1248, 124367.
• Jayagopal, B., & Murugesh, S. (2021). QBD-driven HPLC method of eltrombopag olamine: Degradation pathway proposal, structure elucidation, and in silico toxicity prediction. Journal of Pharmaceutical and Biomedical Analysis, 203, 114231.
• Kaduk, J. A., Gindhart, A. M., & Blanton, T. N. (2021). Crystal structure of eltrombopag olamine form I,(C2H8NO)2(C25H20N4O4). Powder Diffraction, 36(2), 100-106.
• Patel, A. I., Gosai, S., Jadav, K., Vyas, A. J., Patel, A. B., & Patel, N. K. (2020). Stability indicating analytical method development and validation of eltrombopag olamine in tablet dosage form by RP-UPLC. Journal of the Turkish Chemical Society Section A: Chemistry, 7(3), 845-850.